Utah People's Post

The Latest News from the Beehive State

Wednesday, May 18, 2022
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / FDA delays decision on Orexigen’s obesity drug Contrave on potential heart risks  

FDA delays decision on Orexigen’s obesity drug Contrave on potential heart risks  

June 12, 2014 Posted by Contributor

The Food and Drug Administration (FDA) has delayed its decision on the marketing application of drugmaker Orexigen Therapeutics Inc over its obesity drug, Contrave.

The application has been delayed by three months. This move has badly affected the company’s shares as it was recorded down as much as 20 percent on Wednesday.

Contrave is a combination of the antidepressant bupropion and Orexigen’s formulation of naltrexone, designed to prevent drug dependence.

The company said that the federal agency has given indication that the extension was called for to reach agreement on packaging and other post-marketing obligations related to the evaluation of potential heart risks associated with the drug.

Muscular dystrophy first ever drug wins approval from EU

FDA delays decision on Orexigen’s obesity drug Contrave on potential heart risks

Meanwhile, the analysts sounded affirmative over FDA approval as the agency and Orexigen were in talks over the package insert and other post-marketing requirements.

“The ongoing discussions suggest that the regulator has become more comfortable with contrave’s risk/benefit profile,” Wells Fargo analyst Brian Abrahams wrote in a note.

Meanwhile, the federal agency has asked Orexigen to conduct additional trials to assess potential heart risk of the drug. Contrave was rejected by the FDA in 2011 over the health woes.

A statement released by the company in November last year said that an interim analysis of an 8,900-patient study showed that overweight and obese patients receiving contrave did not have a higher heart risk compared with those on a placebo.

Obesity is the root cause of many lifestyle diseases that are leading to preventable deaths in U.S.  In the past four decades, obesity rates in the US have soared, and kids ages six to 11 have been hit the hardest.

More than a third of all U.S. adults and nearly 17 percent of children between the ages of 2 and 19 are obese, according to the Centers for Disease Control and Prevention.

A 2012 report in the Journal of Health Economics shows that obesity accounts for nearly $200 billion a year in U.S. medical spending which is more than 20 percent of national healthcare costs.

 

Share this:

  • Tweet
  • Share on Tumblr

Filed Under: Health Tagged With: Contrave, FDA, Orexigen, Orexigen’s obesity drug

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

June 29, 2018 By Amelia Donovan

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

June 29, 2018 By Amelia Donovan

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

June 28, 2018 By Amelia Donovan

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

June 27, 2018 By Amelia Donovan

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

June 27, 2018 By Amelia Donovan

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

June 26, 2018 By Amelia Donovan

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

June 25, 2018 By Amelia Donovan

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

June 23, 2018 By Amelia Donovan

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

June 22, 2018 By Amelia Donovan

456 People Dead at U.K. Hospital after Taking too Many Painkillers

June 21, 2018 By Amelia Donovan

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

June 20, 2018 By Amelia Donovan

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

    Jun 29, 2018
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

    Jun 29, 2018
  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

    Jun 27, 2018
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

    Jun 25, 2018
  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

    Jun 22, 2018
  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

    Jun 21, 2018
  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

    Jun 19, 2018
  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

    Jun 18, 2018
  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

    Jun 15, 2018
  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

    Jun 13, 2018

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2022 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact